Recently, maintenance of sorafenib, another first generation inhibitor, following allogeneic HSCT has shown encouraging results in FLT3-mutated AML by reducing the post-transplant relapse rate [114, 115]. The gene discussed is FLT3; the disease is acute myeloid leukemia.